Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BML ( (JP:4694) ) has issued an update.
BML, Inc., a Japan-based clinical testing and diagnostic services provider listed on the Tokyo Prime Market, has issued a correction to its previously disclosed consolidated earnings report for the third quarter of fiscal 2024. The revision updates key balance sheet figures, including total assets and the equity ratio, while net assets and equity capital remain unchanged.
The company now reports total assets of ¥179,251 million as of December 31, 2024, up ¥2,866 million from the previous fiscal year-end, compared with the earlier, lower figure of ¥173,867 million. The corrected equity ratio is 71.2%, indicating a larger asset base but slightly lower capital efficiency than initially stated, a technical adjustment that clarifies BML’s financial position for investors without materially altering its net asset levels.
The most recent analyst rating on (JP:4694) stock is a Hold with a Yen4260.00 price target. To see the full list of analyst forecasts on BML stock, see the JP:4694 Stock Forecast page.
More about BML
BML, Inc. is a Japan-based company listed on the Tokyo Stock Exchange Prime Market under securities code 4694. The company operates in the medical and healthcare services sector, focusing on clinical testing and related diagnostic support services for medical institutions and other healthcare stakeholders in Japan.
YTD Price Performance: 3.63%
Average Trading Volume: 59,994
Technical Sentiment Signal: Buy
Current Market Cap: Yen149.6B
For an in-depth examination of 4694 stock, go to TipRanks’ Overview page.